Aesica Extends Aseptic Facilities to Include Pre-filled Syringes
Aesica expands aseptic capabilities at its Nottingham, UK site with the acquisition of new pre-filled syringes manufacturing equipment.
The CDMO Aesica is expanding its aseptic capabilities at its site in Nottingham, United Kingdom with new prefilled syringes manufacturing equipment capable of processing 5000 units/batch. The equipment is currently undergoing validation through process simulation trials. The company’s total investment is more than £500,000 ($797,395), and completion of the validation process is expected to be completed by January 2014. The company’s new equipment also enables production of other product forms, such as pen and cartridge syringes and nasal devices. Over the next three years, Aesica is targeting production of 900,000 units and is in advanced discussions with one company for the scale-up of a clinical trial product for which a joint validation is pending.
Source: Aesica
Shilpa Medicare Launches ‘Hybrid CDMO’ at DCAT Week 2025
March 17th 2025This model is being positioned by Shilpa as a dual approach that offers comprehensive discovery, clinical, and commercial outsourcing services in addition to commercially ready, “off-the-shelf” novel formulations for b2b licensing.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
